Saturnino Haya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Saturnino Haya has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Santiago Bonanad
Coagulation Disorders Unit, Department of Hematology, Hospital Universitario y Politécnico La Fe, 46026 Valencia, Spain
5 shared publications - Juan Eduardo Megías-Vericat
Pharmacy Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain
3 shared publications Ana Rosa Cid
Unit of Hemostasis and Thrombosis, Department of Hematology, La Fe Polytechnic and University Hospital, Valencia, Spain
2 shared publications- Ana Rosa Cid
Haematology Service Hospital Universitario y Politécnico La Fe Valencia Spain
2 shared publications - José Luis Poveda-Andrés
Management Department, Hospital Universitari i Politècnic La Fe, València, Spain
2 shared publications - Maria Choví-Trull
Pharmacy Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain
2 shared publications
Latest Publications
- Open Access
- 17 October 2025
- Published by MDPI AG in Hematology Reports
- Vol. 17 (5) , 53
Real-World Assessment of Pharmacokinetics, Clinical Outcomes, and Costs After Switching from Standard Half-Life to Extended Half-Life FVIII in Well-Controlled Hemophilia A Patients
Objective: This study aimed to analyze pharmacokinetic and clinical parameters (bleeding rates and joint health) before and after switching from standard half-life (SHL) factor VIII (FVIII) to extended half-life (EHL) PEGylated turoctocog alfa pegol in patients with severe/moderate hemophilia A (HA) on prophylaxis, one year prior to and following the switch in a real-world setting. Methods: A single-center, comparative, observational, sequential, retrospective, multidisciplinary study was designed. The population pharmacokinetic parameters were estimated using the WAPPS-Hemo® platform. The annualized bleeding rate (including total and joint bleeds), joint health (Hemophilia Joint Health Score), FVIII consumption, administration frequency, and treatment costs were analyzed. Results: Eight patients with severe (n = 7) or moderate (n = 1) HA on prophylaxis were included after switching to turoctocog alfa pegol. With this regimen, the median FVIII half-life was 16.8 (15.2–19.1) hours, the area under the curve (AUC) was 18,182 (12,879–21,214) IU·h/dL, and the incremental recovery was 2.2 IU/dL per (1.6–2.4) IU/kg. The patients required a median of 2.0 infusions per week (2.0–2.0), corresponding to a weekly consumption of 57.8 (54.2–61.1) IU/kg. Clinically, the prophylactic regimen was associated with fewer infusions per week, stable joint health, and a reduction in overall treatment costs. Conclusions: Prophylaxis with turoctocog alfa pegol provided the expected pharmacokinetic profile of an EHL-FVIII concentrate, enabled a lower infusion frequency, and was linked to a decreased treatment burden and cost while maintaining joint health.
- 17 October 2025
- Published by MDPI AG in Hematology Reports
- Vol. 17 (5) , 53
Open AccessReal-World Assessment of Pharmacokinetics, Clinical Outcomes, and Costs After Switching from Standard Half-Life to Extended Half-Life FVIII in Well-Controlled Hemophilia A Patients
Objective: This study aimed to analyze pharmacokinetic and clinical parameters (bleeding rates and joint health) before and after switching from standard half-life (SHL) factor VIII (FVIII) to extended half-life (EHL) PEGylated turoctocog alfa pegol in patients with severe/moderate hemophilia A (HA) on prophylaxis, one year prior to and following the switch in a real-world setting. Methods: A single-center, comparative, observational, sequential, retrospective, multidisciplinary study was designed. The population pharmacokinetic parameters were estimated using the WAPPS-Hemo® platform. The annualized bleeding rate (including total and joint bleeds), joint health (Hemophilia Joint Health Score), FVIII consumption, administration frequency, and treatment costs were analyzed. Results: Eight patients with severe (n = 7) or moderate (n = 1) HA on prophylaxis were included after switching to turoctocog alfa pegol. With this regimen, the median FVIII half-life was 16.8 (15.2–19.1) hours, the area under the curve (AUC) was 18,182 (12,879–21,214) IU·h/dL, and the incremental recovery was 2.2 IU/dL per (1.6–2.4) IU/kg. The patients required a median of 2.0 infusions per week (2.0–2.0), corresponding to a weekly consumption of 57.8 (54.2–61.1) IU/kg. Clinically, the prophylactic regimen was associated with fewer infusions per week, stable joint health, and a reduction in overall treatment costs. Conclusions: Prophylaxis with turoctocog alfa pegol provided the expected pharmacokinetic profile of an EHL-FVIII concentrate, enabled a lower infusion frequency, and was linked to a decreased treatment burden and cost while maintaining joint health.
- Open Access
- 13 April 2025
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 31
Predicting Thrombophilia in Preeclampsia: Is Universal Testing Necessary?
Introduction: Thrombophilia (TP) has been proposed as a potential contributor to preeclampsia (PE). However, there is not a clear consensus on testing PE patients for TP due to contradictory evidences on this association. This study aims to identify what conditions of women with PE are associated with acquired and hereditary TP, and, additionally, to build a model of TP probability using these characteristics. Material and Methods: Retrospective unicentric analysis of women diagnosed with PE referred for TP testing between May 2019 and May 2024. Results: In 95 women, 19 (20%) tested positive for TP, of which nine (47%) had antiphospholipid syndrome (APS), six (32%) were heterozygous for PT G20210A, two (11%) had ADAMTS13 deficiency, one (5%) had PS deficiency and one (5%) had heterozygous FV Leiden. In multivariate analysis, intrauterine growth retardation (IUGR; odds ratio (OR) 0.08, 95% confidence interval (CI) 0.01-0.55) and history of previous abortions (OR 0.22, 95%CI 0.06-0.96) were negatively associated with TP. The group of women with both, one or none of those traits showed respectively a TP prevalence of 0%, 15% and 32%. The higher the prevalence of TP, the lower the incidence of placental insufficiency and prematurity ( P < .05). Conclusions: In pregnant women with PE, a history of previous abortions and IUGR were independently associated with the absence of TP. Women without these characteristics would probably benefit most from a Hematology consultation that includes a TP screening. A multinational standard TP screening framework for future studies is warranted to further our understanding of the role of TP in PE and to identify risk-groups for testing.
- 13 April 2025
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 31
Open AccessPredicting Thrombophilia in Preeclampsia: Is Universal Testing Necessary?
Introduction: Thrombophilia (TP) has been proposed as a potential contributor to preeclampsia (PE). However, there is not a clear consensus on testing PE patients for TP due to contradictory evidences on this association. This study aims to identify what conditions of women with PE are associated with acquired and hereditary TP, and, additionally, to build a model of TP probability using these characteristics. Material and Methods: Retrospective unicentric analysis of women diagnosed with PE referred for TP testing between May 2019 and May 2024. Results: In 95 women, 19 (20%) tested positive for TP, of which nine (47%) had antiphospholipid syndrome (APS), six (32%) were heterozygous for PT G20210A, two (11%) had ADAMTS13 deficiency, one (5%) had PS deficiency and one (5%) had heterozygous FV Leiden. In multivariate analysis, intrauterine growth retardation (IUGR; odds ratio (OR) 0.08, 95% confidence interval (CI) 0.01-0.55) and history of previous abortions (OR 0.22, 95%CI 0.06-0.96) were negatively associated with TP. The group of women with both, one or none of those traits showed respectively a TP prevalence of 0%, 15% and 32%. The higher the prevalence of TP, the lower the incidence of placental insufficiency and prematurity ( P < .05). Conclusions: In pregnant women with PE, a history of previous abortions and IUGR were independently associated with the absence of TP. Women without these characteristics would probably benefit most from a Hematology consultation that includes a TP screening. A multinational standard TP screening framework for future studies is warranted to further our understanding of the role of TP in PE and to identify risk-groups for testing.
- 23 November 2023
- Published by Elsevier in Thrombosis Research
- Vol. 233, 135-137
Real-world analysis of the PK-guided switch from standard half-life factor VIII to efmoroctocog alfa
- 23 November 2023
- Published by Elsevier in Thrombosis Research
- Vol. 233, 135-137
Real-world analysis of the PK-guided switch from standard half-life factor VIII to efmoroctocog alfa
- Open Access
- 1 October 2023
- Published by PAGEPress Publications in Bleeding, Thrombosis and Vascular Biology
- Vol. 2 (4)
Allopurinol-induced acquired von Willebrand syndrome
Acquired von Willebrand syndrome (AVWS) is a relatively infrequent but often overlooked finding when testing for von Willebrand factor (VWF) levels in a patient with mucocutaneous bleeding. Known causes include cardiovascular disorders, hematologic and solid tumors, autoimmune disorders, hypothyroidism, and drugs. An incoercible oral bleeding after a two-teeth removal in a patient with a mechanical aortic valve eventually raised suspicion about an AVWS that was confirmed through laboratory testing. Substitution therapy with an exogenous VWF factor was required to control the bleeding. Known causes of AVWS, including Heyde’s syndrome, were ruled out. VWF levels finally normalized two days after suspension of allopurinol, which the patient received for symptomatic hyperuricemia, leading to his complete recovery and early discharge without any other complications. AVWS is an underdiagnosed entity due to a lack of testing. Allopurinol has never been postured before as a possible etiology and should be evaluated when reaching a diagnosis.
- 1 October 2023
- Published by PAGEPress Publications in Bleeding, Thrombosis and Vascular Biology
- Vol. 2 (4)
Open AccessAllopurinol-induced acquired von Willebrand syndrome
Acquired von Willebrand syndrome (AVWS) is a relatively infrequent but often overlooked finding when testing for von Willebrand factor (VWF) levels in a patient with mucocutaneous bleeding. Known causes include cardiovascular disorders, hematologic and solid tumors, autoimmune disorders, hypothyroidism, and drugs. An incoercible oral bleeding after a two-teeth removal in a patient with a mechanical aortic valve eventually raised suspicion about an AVWS that was confirmed through laboratory testing. Substitution therapy with an exogenous VWF factor was required to control the bleeding. Known causes of AVWS, including Heyde’s syndrome, were ruled out. VWF levels finally normalized two days after suspension of allopurinol, which the patient received for symptomatic hyperuricemia, leading to his complete recovery and early discharge without any other complications. AVWS is an underdiagnosed entity due to a lack of testing. Allopurinol has never been postured before as a possible etiology and should be evaluated when reaching a diagnosis.
- Open Access
- 14 September 2021
- Published by American Society of Hematology in Blood Advances
- Vol. 5 (19) , 3821-3829
Management of acquired hemophilia A: results from the Spanish registry
The Spanish Acquired Hemophilia A (AHA) Registry is intended to update the status of AHA in Spain. One hundred and fifty-four patients were included and retrospectively followed for a median of 12 months. Patients were predominantly male (56.3%), with median age at diagnosis of 74 years. AHA was more frequently idiopathic (44.1%) and autoimmune disorder-associated (31.7%). Thirty-four percent of patients were on antithrombotic therapy at diagnosis. Hemostatic treatment was used in 70% of patients. Recombinant activated factor VII was more frequently infused (60.3% vs 20.6% activated prothrombin complex concentrate). Only 1 patient did not achieve control of hemorrhage. Complete remission (CR) was achieved by 84.2% of cases after immunosuppressive therapy. Steroids alone were less efficient than the other strategies (68.2% vs 87.2%, P = .049), whereas no differences existed among these (steroids/cyclophosphamide, 88.5%, vs steroids/calcineurin inhibitors, 81.2%, vs rituximab-based regimens, 87.5%). Female sex and high inhibitor levels influenced CR negatively. Thirty-six deaths (23.8%) were reported. Main causes of death were infection (15 patients, 9.9%) and hemorrhage (5 patients, 3.3%). All hemorrhage-related and half the infection-related deaths occurred within 2 months of diagnosis. Prior antithrombotic therapy was inversely associated with survival, irrespective of age. Median age of nonsurvivors was significantly higher (79 vs 73 years in survivors). Patients dying of infection were older than the other nonsurvivors (85 vs 78 years). In summary, fatal infection in the first months is common in our series. Antithrombotic therapy is associated with mortality. Particular care should be taken to avoid misdiagnosis.
- 14 September 2021
- Published by American Society of Hematology in Blood Advances
- Vol. 5 (19) , 3821-3829
Open AccessManagement of acquired hemophilia A: results from the Spanish registry
The Spanish Acquired Hemophilia A (AHA) Registry is intended to update the status of AHA in Spain. One hundred and fifty-four patients were included and retrospectively followed for a median of 12 months. Patients were predominantly male (56.3%), with median age at diagnosis of 74 years. AHA was more frequently idiopathic (44.1%) and autoimmune disorder-associated (31.7%). Thirty-four percent of patients were on antithrombotic therapy at diagnosis. Hemostatic treatment was used in 70% of patients. Recombinant activated factor VII was more frequently infused (60.3% vs 20.6% activated prothrombin complex concentrate). Only 1 patient did not achieve control of hemorrhage. Complete remission (CR) was achieved by 84.2% of cases after immunosuppressive therapy. Steroids alone were less efficient than the other strategies (68.2% vs 87.2%, P = .049), whereas no differences existed among these (steroids/cyclophosphamide, 88.5%, vs steroids/calcineurin inhibitors, 81.2%, vs rituximab-based regimens, 87.5%). Female sex and high inhibitor levels influenced CR negatively. Thirty-six deaths (23.8%) were reported. Main causes of death were infection (15 patients, 9.9%) and hemorrhage (5 patients, 3.3%). All hemorrhage-related and half the infection-related deaths occurred within 2 months of diagnosis. Prior antithrombotic therapy was inversely associated with survival, irrespective of age. Median age of nonsurvivors was significantly higher (79 vs 73 years in survivors). Patients dying of infection were older than the other nonsurvivors (85 vs 78 years). In summary, fatal infection in the first months is common in our series. Antithrombotic therapy is associated with mortality. Particular care should be taken to avoid misdiagnosis.
- Open Access
- 3 January 2019
- Published by Wiley in Haemophilia
- Vol. 25 (2) , E97-E100
Predictive factors of immune tolerance treatment response in severe haemophilia A patients with inhibitors: A real‐world report from a single centre, mixed retrospective‐prospective long‐term study
- 3 January 2019
- Published by Wiley in Haemophilia
- Vol. 25 (2) , E97-E100
Open AccessPredictive factors of immune tolerance treatment response in severe haemophilia A patients with inhibitors: A real‐world report from a single centre, mixed retrospective‐prospective long‐term study
- 1 February 2013
- Published by Springer Nature in Tijdschrift voor kindergeneeskunde
- Vol. 81 (S1) , 38
Identification of 18 High Risk F8 Mutations for Inhibitor Development in 2,700 Non-Severe Hemophilia A Patients
- 1 February 2013
- Published by Springer Nature in Tijdschrift voor kindergeneeskunde
- Vol. 81 (S1) , 38
Identification of 18 High Risk F8 Mutations for Inhibitor Development in 2,700 Non-Severe Hemophilia A Patients